Developed a plan for the strategic development of the future pharmaceutical plant, taking into account the latest industry trends

1. Implemented Power BI analytics in the company's business processes2. Analyzed many drugs from various nosologies (oncology, diabetes mellitus, rheumatology, cardiology, orphan diseases): analysis of the mechanism of action and medical information, competitors, SWOT analysis, market analysis, sales forecast3. Developed a business model for the planned pharmaceutical plant (P&L, CashFlow, NPV, IRR). The project received the approval of the special economic zone

1. Led 10 researchers in biotechnology, genetic engineering and cytology projects2. Created and filed an application for Skolkovo Participant status, which received approval

1. Participated in adeno-associated viral vectors production bioprocess development. Introduced DoE platform to increase the development process efficiency2. Developed E. coli fermentation process for plasmid DNA production

Laboratory Management:1. Conducted scientific research for approaches to the effective production of various recombinant proteins in E. coli. Fermentation processes were developed on Sartorius Biostat B with working volume 5 l and then scaled up to the 150 l bioreactor2. Organized screening studies of producer strains, media composition, cultivation conditions3. Formed a team. Paid great attention to professional development of staff4. The laboratory developed highly productive fermentation processes for producers of various therapeutic molecules (Fab, Fc-fusion protein, insulin and analogues) over the year under my leadershipProject Management:1. Developed the biotechnology project schedule from producer strain creation to preclinical studies2. Regularly reported on the project progress to the top management of the company

1. Participated in different stages of drug research and development, from molecular cloning to in vitro evaluation of biological activity2. Created a number of genetic constructs for the expression of recombinant proteins in both the cytoplasm and the periplasm of E. coli. Conducted screening studies of producer strains. The selected producer strains have been successfully used to produce recombinant therapeutic molecules.3. Conducted studies of the biological activity of a number of drugs using cell-based and biochemical methods. The results of the studies were included in the CTD